Allyx Therapeutics has received a $3.3 million grant from the National Institutes of Health (NIH) to initiate a Phase 1 clinical trial to evaluate the interaction of its investigational oral therapy ALX-001 with other medications and assess how the drug can affect patients who take multiple medications. The grant,…
News
Researchers have identified six probiotics — live bacteria usually used as dietary supplements to help with digestion — with the potential to be used as an add-on to standard treatment for Parkinson’s disease. In a study with bacteria collected from fecal samples, the researchers observed that the bacterial strains…
Treatment with the experimental gene therapy AAV-GAD led to significant easing of motor symptoms and improved life quality for most people with Parkinson’s disease in an early clinical trial, according to new data announced by the therapy’s developer MeiraGTx. “We are excited about these impressive clinical data…
A novel technology based on gene therapy enables precise and noninvasive control of specific brain circuits using magnetic fields, allowing select nerve cells to be turned on or off, a study reports. This magnetogenetics technology — a result of collaboration between Weill Cornell Medicine at Cornell University, The Rockefeller University,…
Neural microtissues derived from pluripotent stem cells (iPSCs) can replace dopaminergic neurons, the nerve cells that are lost in Parkinson’s disease, and restore motor function when grown into tiny capsules and transplanted into the brains of model rats, a study led by TreeFrog Therapeutics found. “TreeFrog Therapeutics has…
Booster Therapeutics announced its launch and the start of work into therapeutics that improve the body’s ability to clear itself of the defective, disease-causing proteins that drive Parkinson’s disease and other neurodegenerative conditions. The company, which is based in Berlin and whose opening was supported by $15 million…
Amprion said it has raised the initial $6 million of a $15 million financing deal that will help develop and commercialize SAAmplify, its diagnostic test for Parkinson’s disease and other neurodegenerative conditions linked to the formation of toxic clumps by the protein alpha-synuclein. The test, SAAmplify, was…
Both a misfolded form of the alpha-synuclein protein and an inflammatory cue are needed to trigger the Lewy bodies that drive the death of dopaminergic neurons in the brains of people with Parkinson’s disease, according to a study in human stem cells. “The results support previous research showing that…
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded a second research grant of $2.5 million to Selonterra to advance the California-based company’s preclinical development of new therapeutic compounds targeting the genetic causes of Parkinson’s disease. Selonterra specifically will be testing whether compounds that…
New U.S. Department of Defense-funded research at Binghamton University in New York is investigating the underlying causes of neuropsychiatric symptoms — those that result from medical conditions involving both neurologic and psychiatric components — in people with Parkinson’s disease. The four-year grant, totaling $3 million, is shared between Binghamton,…
Recent Posts
- Blocking 2 proteins could slow Parkinson’s progression: Study
- How to minimize stress while traveling with Parkinson’s disease
- New PET tracer helps scientists ‘see’ Parkinson’s toxic protein clumps
- Tech duo to advance brain-penetrating drugs for CNS disorders
- New trial offers extended buntanetap access for people with Parkinson’s